Figure 2.

In vivo efficacy with 27 in WiDr tumor xenograft model: WiDr cells were implanted subcutaneously in the right flank of female BALB/c nude mice. Treatments were started on day 6 of implant. Mice were randomly assigned to three groups (n = 8 mice per group). Group 1 was administered with 100 mg/kg, oral gavage, qid; group 2 received 50 mg/kg, ip, bid. Tumor volumes were recorded every 2 days. The study was carried out for 21 days. Mann–Whitney test was used to compare the treated and untreated groups. *P ≤ 0.05.